ReviewDrugs2010
Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices.
Review in Drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
140 citing papers in PubMed, 3 syntheses or guidelines pooled it, 378 citations in OpenAlex.
- "One Health" perspective on prevalence of co-existing extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae: a comprehensive systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2023Pooled it
- A Systematic Review on the Occurrence of Antimicrobial-ResistantBioMed research international · 2023Pooled it
- Prevalence of extended-spectrum-β-lactamase-producingAntimicrobial resistance and infection control · 2018Pooled it
- Review
- Klebsiella genus as driver of human disease: from infections to non-communicable disorders.Nature reviews. Microbiology · 2026Review
- The effect of papain on some bacterial pathogens in poultry meat.Poultry science · 2026Article
- From ecology to evolution: plasmid- and colicin-mediated persistence of antibiotic-resistantmSystems · 2026Article
- Recurrent and Multidrug-Resistant UTI Treatments in Kidney Transplant Patients: A Retrospective Study from Saudi Arabia.Antibiotics (Basel, Switzerland) · 2025Article
- Molecular characterization of extended spectrum beta lactamase producing Escherichia coli in two different wastewater treatment plants in Hatay Province, Türkiye.Scientific reports · 2025Article
- Survey of the antimicrobial susceptibility ofThe Canadian veterinary journal = La revue veterinaire canadienne · 2025Article
- Comprehensive Analysis ofMicroorganisms · 2025Article
- CTX-M-ProducingInfection and drug resistance · 2025Review
- Antimicrobial Resistance in African Great Apes.Antibiotics (Basel, Switzerland) · 2024Review
- Trends in the Prevalence of Antimicrobial Resistance in Escherichia coli Isolated from Outpatient Urine Cultures in French Amazonia.The American journal of tropical medicine and hygiene · 2024Article
- Investigation of Patients Receiving Ceftazidime-Avibactam (CZA) in an Intensive Care Unit: A Retrospective Study from a Tertiary Hospital.Journal of clinical practice and research · 2024Article
- Thematic description of factors linked with extended-spectrum beta-lactamase-producing Enterobacteriaceae in humans.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2024Article
- Review
- Optimized Treatment of Nosocomial Peritonitis.Antibiotics (Basel, Switzerland) · 2023Review
- Article
- Assesment of polyphenolic compounds against biofilms produced by clinicalSaudi journal of biological sciences · 2023Article
80 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since 2000, Escherichia coli producing CTX-M enzymes (especially CTX-M-15) have emerged worldwide as important causes of community-onset urinary tract infections (UTIs) and bloodstream infections due to extended-spectrum beta-lactamase (ESBL)-producing bacteria. Molecular epidemiology studies suggested that the sudden worldwide increase of CTX-M-15-producing E. coli is mostly due to a single clone named ST131 and that foreign travel to high-risk areas such as the Indian subcontinent might in part play a role in the spread of this clone across different continents. Empirical antibacterial coverage for these resistant organisms should be considered in community patients presenting with sepsis involving the urinary tract especially if a patient recently travelled to a high-risk area. Infections due to ESBL-producing Enterobacteriaceae are associated with a delay in initiation of appropriate antibacterial therapy, which consequently prolongs hospital stays and increases hospital costs. Failure to initiate appropriate antibacterial therapy from the start appears to be responsible for higher patient mortality. The carbapenems are widely regarded as the drugs of choice for the treatment of severe infections due to ESBL-producing Enterobacteriaceae, although comparative clinical trials are lacking. Agents that may be useful for the treatment of ESBL-associated UTIs include fosfomycin, nitrofurantoin and temocillin. If this emerging public health threat is ignored, it is possible that clinicians may be forced in the near future to use the carbapenems as the first choice for empirical treatment of serious infections associated with UTIs originating from the community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.